Alnylam Pharmaceuticals, Inc.
ALNYBiotechnology
$174.00−25.13%As of Oct 29vs prior close
- Market cap
- $23.3B
- P/E (TTM)
- 9.6×
- P/E (FY1)
- 19.7×
- From 52W high
- −63.87%
- EPS (LTM)
- $17.67
- Revenue (LTM)
- $4.4B
- Net margin
- 54.62%
- Dividend yield
- 0.00%
Nomior Score
60
Anchored CompounderTop 26% of the scored universe
Growth85
Quality70
Value74
Momentum8
Resilience47
Growth
+62.44%revenue a year over 9 fiscal years
FY16 $47.2MLTM $4.4B
Connections
Revenue to profitQ3 FY26
149% of revenue became net profit.
Who owns it
3funds, 1 tracked portfolio